Area of research
Psychiatry and Mental health · Physiology
Research interest
Research interests include Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments, Medical Imaging Techniques and Applications, and Functional Brain Connectivity Studies.
Diagnostic accuracy of plasma p‐tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
β-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
Toward a Universal Readout for<sup>18</sup>F-Labeled Amyloid Tracers: The CAPTAINs Study
Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease
Using subjective cognitive decline to identify high global amyloid in community‐based samples: A cross‐cohort study
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Multisite study of the relationships between <i>antemortem</i> [<sup>11</sup>C]PIB‐PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology
Sex, amyloid, and <i>APOE</i> ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well‐characterized cohorts
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease
MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET